Completed
PHASE3
INTERVENTIONAL
NCT02477644
Platine, Avastin and OLAparib in 1st Line
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Randomized, Double-Blind, Phase III Trial of Olaparib vs. Placebo in Patients with Advanced FIGO Stage IIIB - IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer treated with standard First-Line Treatment, Combining Platinum-Taxane Chemotherapy and Bevacizumab Concurrent with Chemotherapy and in Maintenance.
Detailed Description
Patients with advanced FIGO stage IIIB - IV high grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer treated with standard first-line treatment, combining platinum-taxane chemotherapy and bevacizumab concurrent with chemotherapy and in maintenance.
Interventions
Name:
Olaparib
Type:
DRUG
Description:
Tablets, per os, 300 mg twice daily;
Name:
Placebo
Type:
DRUG
Description:
Tablets, per os, 300 mg twice daily.
Primary Outcomes
Measure:
Efficacy by progression free survival (PFS1)
TimeFrame:
phase up to a total of 15 months
Description:
Trial Information
NCT ID
NCT02477644
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Arcagy Research
Last Updated
December 15, 2025